New combo therapy aims to delay prostate cancer progression
NCT ID NCT04070209
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether adding precise radiation (SBRT) to the hormone therapy darolutamide can delay cancer progression in men with castration-resistant prostate cancer that has only a few new spots of growth. The study involves 66 participants and measures how long it takes for the cancer to worsen. The goal is to postpone the need for stronger, more aggressive treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
darolutamide (a hormone therapy drug) and stereotactic body radiotherapy (SBRT, a precise type of radiation)
What this could lead to
If successful, this approach could delay the need for stronger second-line treatments and help men with prostate cancer maintain a better quality of life for longer.
What could go wrong
This is a small, early-phase pilot study with only 66 participants, so results may not apply to all patients. There is also a risk that the combination may not improve progression-free survival or could cause side effects from radiation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre hospitalier affilié universitaire régional (CHAUR)
Trois-Rivières, Quebec, G8Z 3R9, Canada
-
Centre hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, H2X 3E4, Canada
-
Centre of Applied Urology Research
Halifax, Nova Scotia, B3H 2Y9, Canada
-
Hôpital Fleurimont (CHUS)
Sherbrooke, Quebec, J1H 5N4, Canada
-
Hôpital Maisonneuve-Rosemont
Montreal, Quebec, H1T 2M4, Canada
-
Hôpital de Gatineau
Gatineau, Quebec, J8P 7H2, Canada
-
L'Hôtel-Dieu de Québec (CHUQ)
Québec, Quebec, G1R 2J6, Canada
-
Prostate Cancer Centre
Calgary, Alberta, T2V 1P9, Canada
-
Service d'urologie et Centre de la prostate
Longueuil, Quebec, J4V 2H3, Canada
-
Sir Mortimer JGH
Montreal, Quebec, H3T 1E2, Canada
-
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, L8N 4A6, Canada